Based on the Glaukos Corp stock forecast from 9 analysts, the average analyst target price for Glaukos Corp is USD 134.50 over the next 12 months. Glaukos Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Glaukos Corp is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Glaukos Corp’s stock price was USD 143.04. Glaukos Corp’s stock price has changed by +8.88% over the past week, +12.72% over the past month and +136.27% over the last year.
No recent analyst target price found for Glaukos Corp
No recent average analyst rating found for Glaukos Corp
Company Overview Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California. Read Less
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous hu...Read More
Frequently Asked Questions About Glaukos Corp (GKOS) Stock
Based on ratings from 9 analysts Glaukos Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 14 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on GKOS's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for GKOS is USD 134.50 over the next 12 months. The maximum analyst target price is USD 145 while the minimum anlayst target price is USD 102.
GKOS stock's Price/Earning ratio is 107.86.
Our analysis grades GKOS stock's Price / Earning ratio at F. This means that GKOS stock's Price/Earning ratio is above 63% of the stocks in the Medical Devices sector in the NYE exchange.
Based on this GKOS may be a overvalued for its sector.
The last closing price of GKOS's stock was USD 143.04.
The most recent market capitalization for GKOS is USD 7.82B.
Based on targets from 9 analysts, the average taret price for GKOS is projected at USD 134.50 over the next 12 months.
This means that GKOS's stock price may go down by -5.97% over the next 12 months.
We can't find any ETFs which contains Glaukos Corp's stock.
As per our most recent records Glaukos Corp has 907 Employees.
Glaukos Corp's registered address is One Glaukos Way, Aliso Viejo, CA, United States, 92656.
You can get more information about it from Glaukos Corp's website at https://www.glaukos.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Glaukos Corp (GKOS) Stock
Based on ratings from 9 analysts Glaukos Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 14 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on GKOS's stock to indicate if its a good dividend stock.
Based on targets from 9 analysts, the average taret price for GKOS is USD 134.50 over the next 12 months. The maximum analyst target price is USD 145 while the minimum anlayst target price is USD 102.
GKOS stock's Price/Earning ratio is 107.86.
Our analysis grades GKOS stock's Price / Earning ratio at F. This means that GKOS stock's Price/Earning ratio is above 63% of the stocks in the Medical Devices sector in the NYE exchange.
Based on this GKOS may be a overvalued for its sector.
The last closing price of GKOS's stock was USD 143.04.
The most recent market capitalization for GKOS is USD 7.82B.
Based on targets from 9 analysts, the average taret price for GKOS is projected at USD 134.50 over the next 12 months.
This means that GKOS's stock price may go down by -5.97% over the next 12 months.
We can't find any ETFs which contains Glaukos Corp's stock.
As per our most recent records Glaukos Corp has 907 Employees.
Glaukos Corp's registered address is One Glaukos Way, Aliso Viejo, CA, United States, 92656.
You can get more information about it from Glaukos Corp's website at https://www.glaukos.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for GKOS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
